Hypertension, Essential Clinical Trial
Official title:
Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan, the Loose Combination of Both and the Single Components Alone and to Investigate the Bioequivalence Between the Fixed Dose and the Loose Combination in Healthy Male Volunteers Under Fasting Conditions in an Open Label, Randomized, 4-way-crossover Design
Randomized, open label, single dose, 4-way crossover study to investigate the bioequivalence of a new fixed dose combination tablet of nifedipine GITS and candesartan with the corresponding loose combination and to compare it with the individual drugs
n/a
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03258489 -
Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients
|
N/A | |
| Terminated |
NCT02245230 -
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
|
Phase 1 | |
| Completed |
NCT05631990 -
A Study to Evaluate the Efficacy and Safety of AD-209
|
Phase 2 | |
| Completed |
NCT02466490 -
Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension
|
Phase 3 | |
| Completed |
NCT01350609 -
Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed
|
Phase 1 | |
| Completed |
NCT01303783 -
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
|
Phase 2 | |
| Not yet recruiting |
NCT04332562 -
The Association Between Serum β-hydroxybutyrate and Levels of Systemic Hypertension
|
N/A |